Sickle cell disease cuts US median life expectancy to about 54 years, a 22-year gap, yet hydroxyurea still reaches only a quarter of eligible patients.

Sickle cell disease is an inherited hemoglobinopathy affecting roughly 100,000 Americans, occurring in about 1 in 365 Black or African American births. The homozygous HbSS genotype accounts for around 60% to 65% of cases and carries the most severe phenotype; HbSC disease, about 25%, and HbS/beta-thalassemia, the remainder, are generally milder, with severity tracking residual beta-globin production. Polymerisation of deoxygenated haemoglobin S deforms red cells, driving haemolysis, vaso-occlusion and progressive organ injury from early childhood onward.

The clinical signature is the recurrent vaso-occlusive crisis, layered over cumulative damage such as acute chest syndrome, stroke, pulmonary hypertension and kidney decline. A US modelling study put median life expectancy at about 54 years versus 76 years without the disease, a 22-year gap. Hydroxyurea reduces crises and mortality but reaches only 25% to 30% of eligible patients, the single largest treatment gap in the disease. An estimated 20,000 to 30,000 patients with severe, recurrent disease form the subset for whom one-time gene therapy is now clinically relevant.

A 22-year life-expectancy gap persists despite a therapy that only a quarter use.

Five questions this report answers:

Q1 - How large is the US sickle cell population by genotype and severity?

Q2 - What vaso-occlusive and organ-damage burden drives the 22-year life-expectancy gap?

Q3 - Which patient segment anchors commercial strategy for one-time gene therapy?

Q4 - How many Americans live with sickle cell disease today?

Q5 - Why does hydroxyurea reach only a quarter of eligible patients?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#SickleCellDisease #SCD #GeneTherapy #RareDisease #HealthEquity #USHealthcare

Live report page:  https://axlrx.ai/sickle-cell-disease/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-                    hello@axlrx.ai

Web-                    https://axlrx.ai/